ERDAFITINIB for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where ERDAFITINIB was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for ERDAFITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 255 | 23.1% | 255 | 8 |
| Off label use | 86 | 7.8% | 5 | 16 |
| Diarrhoea | 75 | 6.8% | 5 | 22 |
| Stomatitis | 58 | 5.2% | 6 | 15 |
| Fatigue | 45 | 4.1% | 4 | 13 |
| Onycholysis | 44 | 4.0% | 8 | 15 |
| Disease progression | 41 | 3.7% | 8 | 14 |
| Dry mouth | 41 | 3.7% | 3 | 12 |
| Nail disorder | 40 | 3.6% | 1 | 4 |
| Hyperphosphataemia | 39 | 3.5% | 4 | 11 |
| Dry eye | 38 | 3.4% | 4 | 3 |
| Mucosal inflammation | 35 | 3.2% | 5 | 5 |
| Decreased appetite | 33 | 3.0% | 4 | 17 |
| Drug ineffective | 33 | 3.0% | 8 | 4 |
| Nail discolouration | 31 | 2.8% | 1 | 11 |
Other Indications for ERDAFITINIB
Product used for unknown indication (641)
Transitional cell carcinoma (168)
Bladder cancer (74)
Neoplasm (28)
Cholangiocarcinoma (19)
Metastatic carcinoma of the bladder (18)
Transitional cell carcinoma metastatic (18)
Breast cancer metastatic (13)
Plasma cell myeloma (8)
Urethral cancer (8)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)